AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Verastem, Inc.
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG001V0G978
10.04▼ 0.02 (-0.20%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
10.06
Day's Range
9.71 – 10.22
52-Week Range
3.43 – 10.82
Volume
3.8M
Avg Volume
4.4M
Share Statistics
Shares Outstanding
Employees
102
Exchange
XNAS
Listed
2012-01-27
Share count as of August 3, 2026

Verastem, Inc. (VSTM) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Verastem, Inc. (VSTM)
What is Verastem, Inc.'s Market Cap?
Verastem, Inc.'s Market Cap is $909.3M, based on as-reported figures from SEC (XBRL) filings.
What is Verastem, Inc.'s Price / Sales?
Verastem, Inc.'s Price / Sales is 10.4×, based on as-reported figures from SEC (XBRL) filings.
What is Verastem, Inc.'s Revenue (TTM)?
Verastem, Inc.'s Revenue (TTM) is $87.5M, based on as-reported figures from SEC (XBRL) filings.
What is Verastem, Inc.'s Net Income (TTM)?
Verastem, Inc.'s Net Income (TTM) is -$202.7M, based on as-reported figures from SEC (XBRL) filings.
What is Verastem, Inc.'s EBITDA?
Verastem, Inc.'s EBITDA is -$158.6M, based on as-reported figures from SEC (XBRL) filings.
What is Verastem, Inc.'s Diluted EPS (TTM)?
Verastem, Inc.'s Diluted EPS (TTM) is -2.24, based on as-reported figures from SEC (XBRL) filings.
What is Verastem, Inc.'s EBITDA Margin?
Verastem, Inc.'s EBITDA Margin is -181.2%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · VSTMAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenue:
Revenue—
YoY growth————
Operating expenses:
Cost of sales - product
Cost of sales - intangible amortization
Research and development
Selling, general and administrative
Total operating expenses
% of revenue—340.5%336.5%462.2%
Loss from operations
% of revenue—-240.5%-236.5%-362.2%
Other expense
Interest income
Interest expense
Loss on debt extinguishment——
Change in fair value of warrant liability
Change in fair value of Notes
Net loss before taxes———
Net loss
% of revenue—-196.0%-187.7%-876.3%
Net loss per share-basic (in dollars per share)
Net loss per share-diluted (in dollars per share)